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Abstract
Medullary thyroid cancer (MTC) is an aggressive malignancy responsible for up to 14% of all thyroid cancer-related deaths. It is characterized
by point mutations in the rearranged during transfection (RET) proto-oncogene. The activated RET kinase is known to signal via extracellular
signal regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K), leading to enhanced proliferation and resistance to apoptosis. In the
present work, we have investigated the effect of two serine/threonine-protein kinase B-Raf (BRAF) inhibitors (RAF265 and SB590885), and a
PI3K inhibitor (ZSTK474), on RET-mediated signalling and proliferation in a MTC cell line (TT cells) harbouring the RETC634W activating muta-
tion. The effects of the inhibitors on VEGFR2, PI3K/Akt and mitogen-activated protein kinases signalling pathways, cell cycle, apoptosis and
calcitonin production were also investigated. Only the RAF265+ ZSTK474 combination synergistically reduced the viability of treated cells. We
observed a strong decrease in phosphorylated VEGFR2 for RAF265+ ZSTK474 and a signal reduction in activated Akt for ZSTK474. The
activated ERK signal also decreased after RAF265 and RAF265+ ZSTK474 treatments. Alone and in combination with ZSTK474, RAF265 induced
a sustained increase in necrosis. Only RAF265, alone and combined with ZSTK474, prompted a significant drop in calcitonin production.
Combination therapy using RAF265 and ZSTK47 proved effective in MTC, demonstrating a cytotoxic effect. As the two inhibitors have been
successfully tested individually in clinical trials on other human cancers, our preclinical data support the feasibility of their combined use in
aggressive MTC.
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Introduction
Thyroid cancer is the most common malignant tumour of the endo-
crine system and accounts for approximately 1% of all newly diag-
nosed cancer cases in the United States. [1]. A small proportion of
thyroid malignances are cases of parafollicular or C-cell-derived med-
ullary thyroid cancer (MTC) [2], which is much more aggressive than
the well-differentiated papillary and follicular malignancy and is
reportedly responsible for up to 14% of all deaths related to thyroid
cancer [3]. More than 50% of patients with MTC have cervical lymph
node metastases at the time of their diagnosis, and up to 5% have
distant metastases. Medullary thyroid cancer is usually unresponsive
to conventional cytotoxic chemotherapy and radiation therapy [4],
and it is prone to metastasize early, so the recommended initial treat-
ment usually includes radical excision of the thyroid together with
central neck lymph node dissection [5].
The main secretory product of the parafollicular cells in MTC is
calcitonin (CT), which is therefore the reference tumour marker for
this neoplasm [6].
The rearranged during transfection (RET) proto-oncogene
located on chromosome 10q11.2 codes for a transmembrane recep-
tor (RET) that has tyrosine kinase activity. Point mutations in RET
are identified in about 98% of cases of familial MTC, and in 30–50%*Correspondence to: Loris BERTAZZA
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of sporadic cases [7]. The RET gene encodes the signalling subunit
of a receptor complex for ligands of the glial-derived neurotrophic
factor family [8], which in turn binds to a family of glial cell
line-derived neurotrophic factor (GDNF) family receptor a (GFRa)
co-receptors, consisting of four glycosylphosphatidylinositol-
anchored proteins, GFRa1-4, that form a complex with RET tyrosine
kinase. The function of RET has been extensively studied in vivo,
and in various cell types, in vitro [9, 10]. The activated RET kinase
transmits mitogenic, survival and motogenic signals. Two major sig-
nalling cascades, namely rat sarcoma (Ras) and phosphatidylinositol
3-kinase (PI3K), are triggered by RET (Fig. 1) [11]. In turn, Ras and
PI3K contribute to the activation of many signalling effectors. The
Ras/Raf/MEK/ERK cascade is the best characterized Ras-effector
pathway. There are three Raf serine/threonine kinases (ARAF, BRAF
and CRAF) that activate the MEK-extracellular signal regulated
kinase (ERK) kinase cascade. ERK, in turn, stimulates gene tran-
scription by directly phosphorylating transcription factors or by tar-
geting intracellular kinases [12]. Class I PI3K is constituted by a
regulatory and a catalytic subunit. Upon recruitment to the plasma
membrane by activated RET, PI3K phosphorylates phosphatidylino-
sitol-4, 5-bisphosphate (PIP2) to generate phosphatidylinositol-3, 4,
5-triphosphate (PIP3; Fig. 1). PIP3, in turn, activates downstream
molecules such as Akt (also known as PKB) serine/threonine kinase,
which stimulates the serine/threonine kinase mammalian target of
rapamycin (mTOR). The PI3K/Akt/mTOR cascade is important in
MTC tumorigenesis because of its ability to promote growth and
proliferation and to prevent cell death [13]. Switching off Ras/Raf/
MEK/ERK and PI3K/Akt/mTOR signalling pathways may be of thera-
peutic benefit in patients with oncological disease characterized by
activation of these 2 pathways. In our previous work, we tested
three new drugs, two serine/threonine-protein kinase B-Raf (BRAF)
inhibitors (RAF265 and SB590885) and a PI3K inhibitor (ZSTK474),
on differentiated thyroid cancer cell lines carrying the BRAF V600E
mutation, discovering that the combination of drugs profoundly
affected proliferation via the mitogen-activated protein kinases
(MAPK) and PI3K/Akt signalling pathways [14]. Given the crosstalk
between these pathways, we examined the inhibitory effects of these
compounds, alone or in combination, on an aggressive TT MTC cell
line harbouring the RET C634W activating mutation [15].
Materials and methods
Cell culture
The TT cell line (MTC, human) was obtained from the European
Collection of Cell Cultures (Sigma-Aldrich, Milano, Italy) and cultured in
RPMI 1640 (Gibco - Life Technologies, Carlsbad, CA, USA) supple-
mented with 10% foetal bovine serum (FBS; Gibco), L-glutamine
Fig. 1 Proposed model for multiple-target
inhibitory action in TT cells. This figure
schematically shows the tyrosine kinase
receptors, such as RET, VEGFR2, and
some of their downstream effectors. The
two most important oncogenic signalling
pathways are PI3K/Akt/mTOR and Ras/
Raf/MEK/ERK. Activation of these path-
ways may transduce different transcription
factors and induce tumour cell prolifera-
tion, survival and migration, with subse-
quent tumour growth, lymphangiogenesis/
angiogenesis, and metastasis. RAF265,
SB590885 and ZSTK474 kinase inhibitors
and their targets are shown too. Pathway
map modified from SABiosciences.
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(2 mM) and penicillin-streptomycin (100 IU/ml–100 lg/ml respectively).
Adherent monolayer cells were maintained in T-75 culture flasks and
incubated at 37°C with 5% CO2 until they achieved 85% confluence.
Cells were detached using 0.25% trypsin-EDTA (Sigma-Aldrich) and pla-
ted in T-75 flasks at a density of 2 9 106 cells.
RAF265 was kindly provided by Novartis International (Basel,
Switzerland), SB590885 and ZSTK474 were purchased from Selleck
Chemicals (Houston, TX, USA). The powders were dissolved in a 10 mM
stock solution in dimethyl sulfoxide (DMSO), following the manufacturer’s
instructions.
MTT cell viability assay and drug synergism
The TT cells were plated on 96-well tissue culture microtiter plates at a
density of 1 9 104 cells/well and treated with RAF265, SB590885 and
ZSTK474 at different concentrations (range 0.01–100 lM). MTT cell via-
bility (Sigma-Aldrich) was tested after 72 hrs of treatment, as described
elsewhere [14]. For each drug, we measured the Inhibitory Concentration
50 (IC50, defined as 50% of the inhibitory effect on cell viability). All exper-
iments were performed in quadruplicate and repeated three times.
The combination index (CI) values were calculated using the Compu-
Syn 3.0.1 program (Ting-Chao Chou and Nick Martin). Based on the
dose–response curves, using the MTT assay for cells treated with inhib-
itors, alone or in combination at a constant ratio, a series of CI values
were generated over a range of levels of growth inhibition (GI) from 5%
to 95% of the fraction affected. The values at 50% GI are presented for
the RAF265+ ZSTK474 and SB590885+ ZSTK474 combinations. Syner-
gism, additive effect, and antagonism are defined as CI < 1, CI = 1,
and CI > 1 respectively.
Trypan blue cell viability assay
The cytotoxic effects of RAF265, ZSTK474 ad SB590885, alone and in
combination were confirmed by the Trypan blue dye exclusion method.
The assay was performed at 72 hrs after treatment, using the single
IC50 dose determined by MTT assay. At the end of treatment, cells
were collected by trypsinization, centrifuged and the cell pellet was
resuspended in 1 ml of PBS. Next, 10 ll of the resulting cell suspen-
sion was admixed with 10 ll of Trypan blue (0.4% in PBS). The num-
bers of non-stained viable cells (NSt cells) and stained dead cells (St
cells) were counted using a hemocytometer. Cell viability was then cal-
culated by the following formula:
Viabilityð%Þ ¼ NSt cells
St cellsþ NSt cells 100
Experiments were performed in triplicated and repeated three times.
The results were interpreted as the ratio of viable cells after drug treat-
ments to that of the untreated control.
Western blot analysis
The TT cells were treated for 4 hrs in 60 mm cell culture dishes with
the IC50 concentrations of the drugs, alone and in combination. Pro-
teins were extracted and centrifuged, and the supernatant was collected.
Total proteins were quantified, separated by SDS/PAGE, electro-blotted
onto nitrocellulose membranes and saturated in 5% fat-free dried milk.
Membranes were incubated overnight with primary antibodies and then
incubated with secondary ones (Sigma-Aldrich). Immunoreactivity was
detected with Euroclone ECL long-lasting substrate (Euroclone, Milano,
Italy). The primary antibodies were anti-Erk1/2, anti-phospho-Erk1/2
(Thr202/Tyr204), anti-Akt, anti-phospho-Akt (Ser473), anti-VEGFR2,
anti-phospho-VEGFR2 (Tyr1175), all (1:1000) from Cell Signaling (Dan-
vers, MA, USA), and anti-b-actin (1:5000) from Sigma-Aldrich. Films
were scanned and the band intensity was quantified with ImageJ soft-
ware 1.44p. All experiments were performed in triplicate.
Calcitonin measurement
Calcitonin transcriptional levels were determined by quantitative real-
time PCR (qrtPCR) using the specific TaqMan assay Hs01100741_m1,
and the corresponding quantification with 2DDCt method. TT cells were
treated for 24, 48 and 72 hrs with the drugs, alone and in combination.
The method was validated by verifying the amplification efficiency of the
target gene and the beta-actin housekeeping gene (Hs99999903_m1).
The qrtPCR was performed with TaqMan assays (Life Technologies,
Monza, Italy) in an ABI PRISM 7900 HT Sequence Detection system.
The experiment was performed in triplicate.
Calcitonin secretion was quantified in the TT cells in the conditioned
medium after treatment with the drugs (alone and in combination).
Briefly, cells were plated in 60 mm tissue culture dishes and treated for
24, 48 and 72 hrs. At the end of each time interval, the conditioned
medium was collected and the CT levels were quantified using LIAI-
SON Calcitonin_II-Gen (DiaSorin Inc., Stillwater, MN, USA), an analyti-
cal method that employs a chemiluminescent immunoassay [16]. The
experiment was performed in triplicate.
Cell cycle analysis
Cells were plated in 100 mm cell culture dishes at a density of 2 9 106
cells and treated with the drugs, alone or in combination, for 24 hrs (data
not shown) and 72 hrs, as described elsewhere [14]. Cell cycle analysis
was performed in triplicate using the Cytomics FC500 and the data were
analysed with the CXP software (Beckman Coulter, Fullerton, CA, USA).
Apoptosis
Apoptosis was tested after 48 hrs of treatment with the Annexin V-FITC
kit (BD Biosciences, San Diego, CA, USA), as described previously [14].
Briefly, all cells were plated in 25 cm2 flasks at a density of 1 9 106
cells/well for 2 days, then maintained overnight at 0.1% FBS. The next
day, the cells were treated with the drugs, alone or in combination, for
48 hrs, then trypsinized and harvested by centrifugation. The cells were
then stained with Annexin V-FITC/propidium iodide according to the
manufacturer’s instructions. All analyses were performed in triplicate
using the Cytomics FC500 (Beckman Coulter).
Statistical analysis
Nonlinear regression and sigmoidal dose–response curves were used
to calculate the IC50 values. Normality tests were applied (the
Kolmogorov–Smirnov, D’Agostino and Pearson omnibus normality, and
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Shapiro–Wilk tests), then group comparisons were drawn using either
one-way ANOVA with Bonferroni’s post-hoc test or the unpaired t-test.
Significance was assumed for a P < 0.05. All analyses were run using
GraphPad Prism rel. 5.03 for Windows (GraphPad Software, San Diego,
CA, USA).
Results
IC50 values and synergistic effects of RAF265,
SB590885 and ZSTK474 in the TT cell line
We examined the in vitro effects of RAF265, SB590885 and ZSTK474
on TT cell viability. The IC50 values were measured 72 hrs after treat-
ment (Table 1). RAF265 was the most effective compound, showing
an IC50 = 0.09 lM, while SB590885 showed an IC50 = 3.36 lM,
and ZSTK474 an IC50 = 0.59 lM (Fig. 2A).
A drug synergy analysis was performed to see whether simulta-
neously suppressing the MAPK and PI3K/Akt pathways could have
inhibitory effects on TT cell viability. Using a wide range of doses, we
observed a median CI = 0.22 for the combination RAF265+ ZSTK474,
and CI = 1.03 for SB590885+ ZSTK474 (Table 1). The effects on cell
viability using the IC50 doses, alone and in combination determined
by the MTT assay were confirmed by the Trypan blue assay. After
72 hrs, cells treated with RAF265 and SB590885 alone showed a via-
bility of 58% and 59%, respectively, while the PI3K inhibitor ZSTK474
alone caused a decrease in vitality of 72%, compared to control. The
synergistic combination RAF265+ ZSTK474 showed a viability reduc-
tion of 20%, while SB590885+ ZSTK474 combination showed a via-
bility reduction of 34%, similarly to the additive effect of the two
drugs (Fig. 2B). The effects of the synergic treatments were also
appreciable on the cell’s morphology (Fig. 3).
Effects of the drugs on signalling pathways in
the TT cell line
To show the effects of the BRAF and PI3K inhibitors on their targets,
we used Western blot to test the drugs both separately and in combi-
nation on the phosphorylation of ERK and Akt (Fig. 4A and B). At
basal level the TT cells expressed similar amounts of total Akt and
total ERK. RAF265, alone and in combination with ZSTK474, strongly
inhibited ERK phosphorylation (P < 0.01), while SB590885, alone
and in combination with ZSTK474, induced a smaller but still signifi-
cant reduction in ERK phosphorylation (P < 0.05). Only ZSTK474
alone prompted a significant reduction in the phosphorylation signal
in the Akt signalling pathway compared to the control (P < 0.01).
Table 1 IC50 and CI values for TT cells treated with the RAF265, ZSTK474 and SB590885 inhibitors
Cell line Genotype
IC50 (lM) CI
RAF265 ZSTK474 SB590885 RAF265+ ZSTK474 SB590885+ ZSTK474
TT RETC634W 0.09 0.59 3.36 0.22 1.03
IC50: Inhibitory Concentration 50; CI: combination index.
A B
Fig. 2 Cell viability of TT cells. (A) Cell viability was estimated by MTT assay after 72 hrs of treatment with RAF265, SB590885 and ZSTK474. Each
analysis was performed with 4 replicates and repeated in 3 separate experiments. (B) Effects on cell viability by Trypan blue dye exclusion method
after 72 hrs of treatment with RAF265 (R), ZSTK474 (Z) and SB590885 (S), alone and in combination (R+Z and S+Z) using the single IC50 doses
determined by MTT assay. Each analysis was performed with 3 replicates and repeated in 3 separate experiments.
ª 2015 The Authors.
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As RAF265 also inhibits the VEGFR2 [17], we evaluated the
expression of this receptor in TT cells (Fig. 4A and B). At basal level,
the cells expressed similar amounts of total VEGFR2 with all the treat-
ments. We found phosphorylated VEGFR2 strongly expressed in the
untreated cells, while markedly reduced reactivity was apparent on
the phosphorylated receptor after RAF265 treatment (P < 0.01) and
this effect was enhanced when the RAF265+ ZSTK474 combination
was tested (P < 0.001).
Cell cycle distribution
We analysed the effects of the drugs on TT cell cycle distribution
(Fig. 5). RAF265 was the most effective single drug, inducing a sub-
stantial increase in the sub-G1 phase from 4% in untreated cells to
40% (P < 0.01), with a concomitant G0-G1 phase reduction (from
73% in untreated cells to 48% in treated cells). ZSTK474 and
SB590885 each induced a slight but significant increase in the sub-
G1 phase (P < 0.05). The combination of RAF265+ ZSTK474 was
highly effective in inducing a remarkable increase in the sub-G1
phase, from 4% in untreated cells to 70% (P < 0.001), with a con-
comitant decrease in the G0-G1 phase. The combination of
SB590885+ ZSTK474 induced a moderate increase in the sub-G1
phase, from 4% in untreated cells to 23% (P < 0.01), and a concomi-
tant reduction in the G0-G1 phase.
Apoptosis
Flow cytometry after annexin V-FITC/propidium iodide staining was
performed to discriminate between apoptosis and necrosis (Fig. 6).
The results are shown in a specific flow cytometry diagram, where C3
A B
Fig. 3 Changes in cell morphology follow-
ing drug treatments. Effect of the drugs
on the morphology of cultured human TT
cells after 72 hrs of treatment. (A) No
treatment; (B) RAF265 1 lM + ZSTK474
1 lM.
A B
** **
**
** **
*
*
**
***
*
Fig. 4Western blot analysis. Representa-
tive Western blot of b-actin, ERK, phos-
pho-ERK, Akt, phospho-Akt, VEGFR2,
phospho-VEGFR2 antibodies in TT cells
treated for 4 hrs using IC50 doses. (A)
Ctrl, untreated cells; R, cells treated with
RAF265; Z, cells treated with ZSTK474; S,
cells treated with SB590885; R+Z, cells
treated with RAF265+ZSTK474; S+Z, cells
treated with SB590885+ZSTK474. These
profiles are representative of 3 separate
experiments. (B) Quantitative densitometry
is shown to compare phosphorylated
protein expression as a ratio normalized
to untreated control levels. One-way
ANOVA: *, P < 0.05; **, P < 0.01; ***,
P < 0.001.
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Fig. 5 Cell cycle analysis following drug treatments. Representative cell cycle distribution analysis at 72 hrs for TT cells left untreated or treated with
drugs using IC50 doses. Four cell phases (G2/M, S, G0-G1, sub-G1) with their percentages alongside are indicated in each plot. Representative dis-
tribution of cell cycle analysis, performed in triplicate.
Fig. 6 Apoptosis analysis following drug
treatments. Representative flow cytometry
after annexin V-FITC/propidium iodide
staining in TT cells at 72 hrs. Cells were
treated with all drugs, alone or in combi-
nation, using IC50 doses. Pie graphs indi-
cate the percentages of C1 (dead cells),
C2 (necrosis), C3 (live cells), C4 (early
apoptosis). Results are representative of
three separate experiments.
ª 2015 The Authors.
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indicates live cells, C1 dead cells, C4 early apoptosis and C2 necrosis.
A sustained increase in necrotic TT cells was apparent after treatment
with RAF265, alone and in combination with ZSTK474 (from 2% in
untreated cells to 9% in cells treated with RAF265, and 15% in those
treated with both RAF265 and ZSTK474, P < 0.05). A significant
increase in early apoptosis, compared with the control, was also seen
for ZSTK474, both alone (from 5% to 11%, P < 0.05) and in combi-
nation with SB590885 (from 5% to 12%, P < 0.05).
Effects of drugs on CT gene expression and
secretion in TT cell lines
We examined the effects of the drugs on CT gene expression in vitro.
As shown in Figure 7A, treating the TT cells with RAF265 alone
caused a significant drop in CT mRNA expression, which was espe-
cially evident after 72 hrs. ZSTK474, alone and in combination with
RAF265, took 72 hrs to induce a significant decrease in CT mRNA
expression level. Treatment with SB590885, alone or combined with
ZSTK474, had no effect on CT mRNA levels.
Then we examined the effects of the drugs on CT levels in the TT
cells in the culture medium by chemiluminescent immunoassay. As
shown in Figure 7B, the CT levels dropped rapidly and were signifi-
cantly lower than in the control after treatment with RAF265 alone for
different times (24, 48 and 72 hrs), and after treatment with
RAF265+ ZSTK474 for 72 hrs. Treatment with SB590885, alone or in
combination with ZSTK474, demonstrated no clear effect on CT
secretion (data no shown).
Discussion
There is currently no effective systemic treatment for patients with
metastatic MTC, conventional chemotherapy and/or radiotherapy hav-
ing demonstrated only a limited efficacy in inducing tumour remission
or stabilization [18, 19]. New approaches with tyrosine kinase inhibi-
tors have been found to prolong progressive disease-free survival in
advanced MTC patients, but they demand long-term treatments that
have non-negligible adverse effects [20]. Hence the urgent need for
new therapeutic modalities.
The activated RET kinase is known to signal via Ras/Raf/MEK/ERK
and PI3K/Akt pathways, among others, leading to enhanced prolifera-
tion and resistance to apoptosis [11]. Simultaneously inhibiting
MAPK and PI3K could have a therapeutic effect in patients with onco-
logical diseases carrying these signalling pathways in a constitutively
active state.
The present work aimed to examine the effects of three new
drugs, RAF265, SB590885 and ZSTK474, on a RET-activated TT cell
line model derived from an aggressive medullary thyroid carcinoma.
TT cells retains some differentiated properties of the normal thyroid C
cells such as CT production and are one of the most representative
models for the study of MTC. RAF265 is a BRAF inhibitor compound
specific for the V600E-mutated isoforms that has been designed and
developed primarily for the treatment of locally advanced and meta-
static BRAF-mutated melanoma. A phase 2 clinical trial has just been
completed (ClinicalTrials.gov identifier NCT00304525), the results of
which have yet to be published, but over the years several studies
have demonstrated an effect of this compound in other tumours,
including differentiated thyroid cancers. A previous publication by our
group showed that RAF265 had an inhibitory effect on papillary thy-
roid cancer (PTC) cell lines harbouring the BRAFV600E mutation [14].
RAF265 alone has also already been tested in TT cells, and found to
induce a significant decrease in TT cell viability [21]. The present work
is the first, to the best of our knowledge, to examine MAPK pathway
inhibition by either RAF265 or SB590885 (the latter compound tested
here for the first time) in combination with PI3K pathway inhibition by
ZSTK474. We did not use RAF265 and SB590885 together because
they compete for the same ATP-binding site of the RAF dimer, and
this overlap may limit the effectiveness of the two drugs.
The most evident effects on TT cell viability were obtained by
RAF265, both alone (with an IC50 of 0.09 lM) and in combination
with ZSTK474 (with a median CI of around 0.22). SB590885 was also
A B
Fig. 7 Drug effects on TT calcitonin production. Effect of RAF265 and ZSTK474, alone and in combination, on calcitonin mRNA abundance and
secretion, in TT cells. (A) Calcitonin mRNA expression levels in treated cells, compared with the control, as measured by quantitative PCR at 24, 48
and 72 hrs. (B) Calcitonin secretion in TT cells in conditioned medium, compared with the control, as measured by LIAISON Calcitonin_II-Gen at
24, 48 and 72 hrs. One-way ANOVA: *, P < 0.05.
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effective in reducing TT cell viability on its own, while combining it
with ZSTK474 only showed an additive effect.
A previous report suggested that the effect of a mutated BRAF
inhibitor, RAF265, on a medullary cell line like TT, carrying a wild-type
BRAF but harbouring a RETC634W mutation, could be explained by
an inhibitory effect on the activated RET isoforms [21]. In our work,
we used Western blot analysis to try and see if other cellular path-
ways could be repressed after the RAF265 treatment. In TT cells, the
p-ERK signal was active at the baseline and both BRAF inhibitors were
able to inhibit it, but RAF265 (alone or in combination with ZSTK474)
had the strongest effect, not excluding a direct influence on the wild-
type BRAF isoforms. RAF265 also exerted a direct inhibitory effect on
activated VEGFR2: in our cells, the phosphorylated VEGFR2 signal
(constitutively triggered at basal level) was inhibited by RAF265 alone
and even more so when it was combined with ZSTK474.
When we analysed the effects on cell cycle distribution, we
observed a general increase in the sub-G1 fraction of cells treated
with SB590885+ ZSTK474, and especially with the RAF265+ ZSTK474
combination, with no concomitant increase in the G0-G1 phase.
These results were unexpected and inconsistent with our previous
findings in a PTC model, and with the results obtained with other
kinase inhibitors on differentiated thyroid cancer cell lines. In the
work by Salerno et al., for instance, PLX4032 and PLX4720 (two
BRAF V600E ATP-competitive kinase inhibitors) inhibited G0-G1 and
altered the expression of genes involved in the control from the G1 to
the S phase [22]. The Authors used several thyroid cancer cell lines,
but not MTC, so the effect on the cell cycle in the TT line might be
linked to the specific inhibition of the mutated RET protein.
With the aid of annexin V-FITC/propidium iodide staining, we tried
to elucidate the cell death mechanism underlying the sub-G1 fraction
increase: we found a necrosis-like mechanism with no significant
increase in the apoptotic cell fraction, especially after treatment with
the RAF265+ ZSTK474 combination. The effect of RAF265, alone and
with ZSTK474, appeared to be cytotoxic and not cytostatic. In our
opinion, this last finding seems to be particularly relevant for the pur-
pose of designing future therapies because the main tyrosine kinase
inhibitors currently used in clinical practice have only revealed cyto-
static effects and need to be administered non-stop in MTC patients
[20].
In short, RAF265 has a direct inhibitory effect on upstream signal-
ling pathway receptors (mutated RET and activated VEGFR2), but also
on the BRAF intermediate MAPK pathway effector. This action, com-
bined with the inhibitory effect of ZSTK474 on the p-AKT pathway,
can explain the synergistic effect observed on TT cell line (Fig. 1).
Rearranged during transfection kinase mediates a physiological
pathway that controls CT secretion. Akeno-Stuart et al. have shown
that NVP-AST487 (a N,N0-diphenyl urea with an IC50 of 0.88 lM on
RET kinase) inhibits CT production in TT cells in vitro, also limiting
gene transcription [23]. We quantified CT mRNA and protein produc-
tion and found the same effect in TT cells after RAF265 treatment,
which goes to show that RAF265 has a powerful inhibitory effect on
the CT production pathway, controlled by RET.
This study provides the first demonstration of the strong inhibi-
tory effects of a novel BRAF inhibitor, RAF265, and its synergistic
effect with the PI3K inhibitor ZSTK474, in TT cells harbouring genetic
alterations in RET. More preclinical research on MTC has focused on
RET inhibitors, but to date no studies had examined the possible
effects of RAF inhibitors in MTC. Given the extremely common
genetic alterations in the particularly aggressive and currently untreat-
able MTC, combination therapy with RAF265 and ZSTK47 may prove
effective for this aggressive cancer. As the two inhibitors have been
successfully tested separately in clinical trials on other human can-
cers, the preclinical findings reported in this study warrant clinical tri-
als on their combined use for treating aggressive MTC.
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